CR20210240A - Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina - Google Patents

Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina

Info

Publication number
CR20210240A
CR20210240A CR20210240A CR20210240A CR20210240A CR 20210240 A CR20210240 A CR 20210240A CR 20210240 A CR20210240 A CR 20210240A CR 20210240 A CR20210240 A CR 20210240A CR 20210240 A CR20210240 A CR 20210240A
Authority
CR
Costa Rica
Prior art keywords
orexin receptor
synthetic methods
heterocyclic compounds
receptor modulators
fused heterocyclic
Prior art date
Application number
CR20210240A
Other languages
English (en)
Inventor
Andy Josephina Joannes Huygaerts
Dominique Paul Michel Depré
Kiran Matcha
Dinesh Gala
Luc Jozef Raphael Moens
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR20210240A publication Critical patent/CR20210240A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen procesos para preparar (((3aR,6aS)-5-(4,6-dimetilpirimidin-2-il)hexahidropirrolo[3,4-c]pirrol-2(1H)-il)(2-fluoro-6-(2H-1,2,3-triazol-2-il)fenil)metanona, que son útiles para la fabricación comercial. Dicho compuesto es un modulador del receptor de orexina y puede ser útil en composiciones farmacéuticas y métodos para el tratamiento de estados de enfermedad, trastornos y afecciones mediadas por la actividad de la orexina, tales como insomnio y depresión.
CR20210240A 2018-11-14 2019-11-11 Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina CR20210240A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862760995P 2018-11-14 2018-11-14
PCT/IB2019/059677 WO2020100011A1 (en) 2018-11-14 2019-11-11 Improved synthetic methods of making fused heterocyclic compounds as orexin receptor modulators

Publications (1)

Publication Number Publication Date
CR20210240A true CR20210240A (es) 2021-06-08

Family

ID=70730771

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210240A CR20210240A (es) 2018-11-14 2019-11-11 Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina

Country Status (26)

Country Link
US (1) US12030887B2 (es)
EP (2) EP4428136B1 (es)
JP (1) JP7398452B2 (es)
KR (1) KR102777062B1 (es)
CN (1) CN113038952B (es)
AR (1) AR117074A1 (es)
AU (1) AU2019380072B2 (es)
BR (1) BR112021009211A2 (es)
CR (1) CR20210240A (es)
EA (1) EA202191356A1 (es)
EC (1) ECSP21034253A (es)
ES (2) ES3060483T3 (es)
HR (1) HRP20240743T1 (es)
HU (1) HUE066708T2 (es)
IL (1) IL283067A (es)
JO (1) JOP20210110A1 (es)
MA (2) MA54250A (es)
MX (1) MX2021005698A (es)
PE (1) PE20211470A1 (es)
PH (1) PH12021551054A1 (es)
PL (1) PL3880204T3 (es)
RS (1) RS65638B1 (es)
SG (1) SG11202104886YA (es)
SM (1) SMT202400265T1 (es)
TW (1) TW202039452A (es)
WO (1) WO2020100011A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022194122A1 (zh) * 2021-03-16 2022-09-22 上海翰森生物医药科技有限公司 含氮杂环的多环化合物及其制备方法和应用
AU2023340064A1 (en) * 2022-09-14 2025-03-20 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Free base crystal form of polycyclic compound of nitrogen-containing heterocycle, and preparation method therefor
EP4635949A4 (en) * 2022-12-12 2026-04-01 Jiangsu Nhwa Pharmaceutical Co Ltd SUBSTITUTED TETRAHYDROCYCLOPENTYL[C]PYRROLE DERIVATIVE, PREPARATION PROCESS, INTERMEDIATE AND ASSOCIATED USES
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators
EP4734999A1 (en) 2023-06-29 2026-05-06 Janssen Pharmaceutica NV Method of treating depression using seltorexant
WO2025242852A1 (en) 2024-05-24 2025-11-27 Janssen Pharmaceutica Nv Seltorexant for use in treating major depressive disorder with insomnia symptoms
CN118598880B (zh) * 2024-08-07 2024-11-26 艾斯拓康生物医药(天津)有限公司 一类含氮桥环化合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4341403A1 (de) 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
JP2008540575A (ja) 2005-05-13 2008-11-20 レキシコン・ファーマシューティカルズ・インコーポレーテッド 多環系化合物とその使用の方法
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
WO2008067121A2 (en) 2006-11-07 2008-06-05 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
BRPI0821676A2 (pt) 2007-12-21 2015-06-16 Astrazeneca Ab Composto, composição farmacêutica, e, processo para a preparação dos compostos.
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
ES2585806T3 (es) * 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
US10258038B2 (en) 2014-04-01 2019-04-16 Bayer Cropscience Aktiengesellschaft Use of heterocyclic compounds for controlling nematodes
US9938276B2 (en) * 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
US10131653B2 (en) * 2015-04-24 2018-11-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
HRP20220642T1 (hr) 2016-03-10 2022-06-24 Janssen Pharmaceutica Nv Postupci za liječenje depresije uporabom antagonista receptora oreksina 2
GB201702174D0 (en) 2017-02-09 2017-03-29 Benevolentai Bio Ltd Orexin receptor antagonists

Also Published As

Publication number Publication date
KR102777062B1 (ko) 2025-03-05
EP3880204B1 (en) 2024-05-15
EP3880204A1 (en) 2021-09-22
BR112021009211A2 (pt) 2021-08-03
AR117074A1 (es) 2021-07-07
EA202191356A1 (ru) 2021-08-11
EP3880204C0 (en) 2024-05-15
HUE066708T2 (hu) 2024-09-28
TW202039452A (zh) 2020-11-01
KR20210091726A (ko) 2021-07-22
PE20211470A1 (es) 2021-08-05
AU2019380072A1 (en) 2021-05-27
SG11202104886YA (en) 2021-06-29
US20220009932A1 (en) 2022-01-13
CN113038952A (zh) 2021-06-25
ECSP21034253A (es) 2021-06-30
IL283067A (en) 2021-06-30
MA71707A (fr) 2025-05-30
PL3880204T3 (pl) 2024-09-09
RS65638B1 (sr) 2024-07-31
MA54250A (fr) 2022-02-23
EP3880204A4 (en) 2022-08-17
EP4428136A2 (en) 2024-09-11
EP4428136B1 (en) 2025-11-26
CN113038952B (zh) 2024-08-23
HRP20240743T1 (hr) 2024-08-30
JP2022507361A (ja) 2022-01-18
AU2019380072B2 (en) 2025-03-27
JP7398452B2 (ja) 2023-12-14
WO2020100011A1 (en) 2020-05-22
JOP20210110A1 (ar) 2021-05-16
SMT202400265T1 (it) 2024-07-09
EP4428136A3 (en) 2024-11-06
PH12021551054A1 (en) 2021-12-06
ES2988132T3 (es) 2024-11-19
US12030887B2 (en) 2024-07-09
MX2021005698A (es) 2021-07-07
EP4428136C0 (en) 2025-11-26
CA3118734A1 (en) 2020-05-22
ES3060483T3 (en) 2026-03-26

Similar Documents

Publication Publication Date Title
MX2021005698A (es) Metodos sinteticos mejorados para elaborar compuestos heterociclicos fusionados como moduladores del receptor de orexina.
MX386481B (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
PH12019501254A1 (en) Small molecule inhibitors of the jak family of kinases
SV2018005800A (es) Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4
SA520412192B1 (ar) مشتقات 5-(2-(2، 5-داي فلورو فنيل)بيروليدين-1-يل) -3-(1h-بيرازول-1-يل) بيرازولو[1، 5-a] بيريميدين والمركبات ذات الصلة كمثبطات كيناز trk لعلاج السرطان
MX2010009458A (es) Derivados biciclicos heterociclicos o espirobiciclicos heterociclicos enlazados, de pirazolo[1,5-a]pirimidinas, procedimientos para su preparacion y usos de los mismos.
PH12012500796A1 (en) Disubstituted octahydropyrrolo [3,4-c] pyrroles as orexin receptor modulators
EA201790995A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
TW200621256A (en) Formulations
MX2020012097A (es) Proceso para preparar inhibidores de tirosina cinasa de bruton (btk).
MX2020009586A (es) Compuestos de (2-azabiciclo[3.1.0]hexan-2-il)pirazolo[1,5-a]pirimi dina e imidazo[1,2-b]piridazina sustituidos como inhibidores de cinasas trk.
MX2021015510A (es) Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b.
WO2019089676A8 (en) Antagonists of the muscarinic acetylcholine receptor m4
PH12020551984A1 (en) Small molecule inhibitors of the jak family of kinases
EA202190323A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk
MX390505B (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2
EP3568400C0 (en) PROCESS FOR PREPARING 5-AMINO-6H-THIAZOLO[4,5-D]PYRIMIDINE-2,7-DIONE COMPOUNDS WITH POSITION 3
MX2022001615A (es) Métodos sintéticos mejorados para la elaboración de compuestos de (2h 1,2,3-triazol-2-il)fenilo como moduladores del receptor de orexina.
GB0522082D0 (en) Formulations
HK40047715A (en) Solid forms of n-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide